Latest Regulatory News

Island Pharmaceuticals has appointed Raymond Taylor, a former BioCryst executive with deep Galidesivir expertise and US government funding experience, to accelerate development and procurement efforts for its broad-spectrum antiviral amid rising viral threats.

Comet Ridge has revised its acquisition deal for Santos’ stake in the Mahalo Gas Project, cutting upfront cash and extending deadlines to navigate new government gas reservation policy uncertainty.

Elanor Investors Group has obtained an ASX waiver allowing it to delay issuing stapled securities as part of its acquisition of Singapore-based Firmus Capital until July 10, 2026, due to pending regulatory approvals.

Adherium Limited plans a 1-for-100 share consolidation pending shareholder approval, aiming to reduce share count and enhance marketability.

Argenica Therapeutics has passed a critical FDA genotoxicity test for its stroke drug ARG-007, advancing its IND application and edging closer to Phase 2b clinical trials in the US and Australia.

Eden Innovations appoints former European Parliament member Antanas Guoga to lead EdenShield’s push into European defence and critical infrastructure markets amid surging regional security spending.

Hillgrove Resources has secured an option to earn an 80% stake in the Mutooroo Copper Project through a $10 million pre-feasibility study farm-in with Havilah Resources, aiming to leverage existing infrastructure to boost copper output.

Hillgrove Resources has secured the right to earn an 80% stake in the Mutooroo Copper Project through a farm-in deal with Havilah Resources, leveraging its Kanmantoo processing plant to potentially boost copper output with lower capital risk.

Terrain Minerals is progressing steadily towards a maiden Mineral Resource Estimate (MRE) for its Lightning Gold Project, targeting July 2026. Key technical and regulatory milestones are being ticked off, underpinning the project’s transition from exploration to resource definition.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

TruScreen Group Limited has kicked off a NZ$2.9 million capital raising combining a NZ$1 million placement and a NZ$1.94 million rights issue to fund its global expansion and regulatory compliance efforts. The company reported a 42% jump in product sales for FY2026 and is targeting major public health programs across 14 countries.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.